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Introduction: Helicobacter pylori (H. pylori) is a common infection and known risk factor
for gastric cancer. We assessed cross-sectional and longitudinal associations to study
the impact of H. pylori seropositivity on metabolic diseases.
Methods: Helicobacter pylori seropositivity in serum samples of the KORA study
was analyzed by multiplex serology. We calculated sex-specific prevalence of H. pylori
seropositivity for the year 2007 based on the first follow-up survey (termed F4) of
the KORA study S4. We identified factors associated with H. pylori seropositivity in
the F4 survey. Further, we assessed relative risks of incident metabolic diseases/risk
factors at the time of the second follow-up survey of S4 (termed FF4) and H. pylori
seropositivity at the F4 survey as a determinant. Models were adjusted for age, sex,
overweight status, physical activity, smoking status, education level, alcohol intake, and
other metabolic diseases.
Results: Based on 3,037 persons aged 32 to 82 years, the H. pylori prevalence
for 2007 was 30.2% in men (n = 1,465) and 28.1% in women (n = 1,572).
Increasing age, current smoking, low education and no alcohol intake were significantly
associated with H. pylori seropositivity in the F4 survey. However, no association
between H. pylori seropositivity and BMI, metabolic diseases (type 2 diabetes,
hypertension and dyslipidemia, gout or increased uric acid) and gastrointestinal diseases
(gastritis, inflammatory bowel disease, and gastric or duodenal ulcer) was observed. No
significant associations between H. pylori seropositivity and one of the five investigated
incident metabolic diseases/risk factors were detected in the longitudinal analysis.
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Conclusion: We identified associations between age, smoking, education and alcohol
intake and H. pylori seropositivity but no impact of H. pylori seropositivity on incident
metabolic diseases/risk factors.
Keywords: Helicobacter pylori, multiplex serology, infection, prevalence, metabolic diseases
BACKGROUND
Helicobacter pylori (H. pylori) infection is one of the world’s most
common infections. A recent meta-analysis on global prevalence
of H. pylori infection reported a wide range from 18.9% in
Switzerland up to 87.7% in Nigeria (1). The prevalence in the
African region is∼70%, the highest world-wide and is influenced
by socio-economic status as well as levels of hygiene (1). As the
majority of H. pylori infections are asymptomatic, eradication
therapy is not applied to these persons and the infection persists
over time, leading to inflammatory changes of the gastric mucosa.
A potential risk for severe gastrointestinal diseases including
gastric cancer in persons infected with H. pylori is known (2–5).
In their recent review, Cellini et al. (6) describe the pathogenic
link to be a cross-reactivity mechanism of the H. pylori infection
that induces proliferation of CD4+ T lymphocytes. These are
the lymphocytes that recognize epitopes of H. pylori, which
are structurally similar to those of H+/K+-ATPase (7). In the
absence of peripheral tolerance, a Th1-driven autoreactive clone
is activated (8) when dendritic cells present these shared epitopes
to naïve T cells. Besides gastric cancer, H. pylori infection has
been suggested to be causally linked to a variety of extra-gastric
diseases and metabolic derangements (3, 9). In particular, the
impact of H. pylori seropositivity on newly developed diabetes
mellitus has been studied over the last years providing conflicting
results. A prospective study over 10 years including Latino
elderlies living in California found a positive association between
seropositiveH. pylori status and incident diabetes (10). However,
Yu et al. reported an impact of gastric atrophy but not of
H. pylori infection on the incidence of diabetes (11). Further,
the influence of H. pylori infection on the incidence of other
metabolic disorders, gastrointestinal diseases without gastric
cancer and as well extra-gastric diseases, such as neurological
or hematological diseases, asthma, allergies, immune disorders
or skin diseases, has been studied widely (3, 9, 12). Lastly,
there is a large potential burden of impaired drug absorption
in the stomach, as persistent H. pylori infections can possibly
lead to an altered gastric pH (13). The aim of our study was to
calculate the sex-specific prevalence of H. pylori seropositivity
for the year 2007 based on the follow-up survey F4 of the KORA
S4 study. Secondly, in a cross-sectional approach we aimed to
investigate associations betweenH. pylori seropositivity at F4 and
lifestyle factors, metabolic, gastrointestinal, and other diseases.
Finally, in a prospective design we investigated the association
Abbreviations: H. pylori, helicobacter pylori; BMI, Body mass index; OGT, oral
glucose tolerance; OR, odds ratio; CI, confidence interval; nmol, nanomol; L, liter;
MFI, median fluorescence intensity; CagA, cytotoxin-associated gene-A; KORA,
Cooperative Health Research in the Region Augsburg); S4, KORA Survey 4; F4,
KORA Follow-up of S4; FF4, KORA Second Follow-up of S4.
between seropositiveH. pylori status at F4 and incident metabolic
diseases/risk factors at FF4 (second follow-up of S4) defined
as type 2 diabetes, obesity, relative weight change increase,
hypertension, and dyslipidemia.
SUBJECTS AND METHODS
Our analyses are based on data from the Cooperative Health
Research in the Region of Augsburg (KORA) F4 study (2006–
2008) and the KORA FF4 study (2013–2014). They are both
follow-up examinations of the population-based KORA S4
study (1999–2001), conducted in the city of Augsburg and
two surrounding counties. The design and background of the
KORA studies have been described in detail elsewhere (14). In
brief, medical examinations by trained staff, self-administered
questionnaires and the collection of biosamples were applied
within the studies. Details on the assessment of the variables of
interest are given below. The investigations were carried out in
accordance with the Declaration of Helsinki, including written
informed consent from all participants. The study was approved
by the ethics committee of the Bavarian Chamber of Physicians
(Munich, Germany).
The data set included 3,080 participants at F4. Thereof,
3,037 participants had information on their H. pylori status
at F4 available, but not necessarily at FF4. A subset of 2,075
persons participated in both surveys (F4 and FF4) and had their
H. pylori status at both survey time-points available. Prevalence
ofH. pylori seropositivity and its association with certain diseases
and lifestyle factors was described for participants of the F4
survey. We explored the impact of acute and past H. pylori
infection on incident diseases/risk factors in the longitudinal
design with F4 as baseline and FF4 as follow-up examination to
identify incident diseases.
Definition of Variables and Assessment
Antibody responses to H. pylori were determined by multiplex
serology as described elsewhere (15). Briefly, 15H. pylori proteins
were recombinantly expressed as GST-X-tag fusion proteins and
each antigen affinity-purified on distinct fluorescently labeled
glutathione-casein coated bead sets (SeroMap, Luminex Corp.,
Austin, Tx, USA). A mix of these differently labeled, antigen-
coupled bead sets was incubated with serum. A Luminex xMAP
analyzer (Luminex Corp., Austin, Tx, USA) identifies the bead set
and simultaneously quantifies bound serum IgA, IgM, and IgG by
a reporter fluorescent conjugate, Streptavidin-R-Phycoerythrin.
The level of antibody response is given as median fluorescence
intensity (MFI). Antigen specific cut-offs were applied and
seropositivity to H. pylori defined as being positive to at least
4 antigens.
Frontiers in Public Health | www.frontiersin.org 2 April 2019 | Volume 7 | Article 96
Wawro et al. Helicobacter pylori Seropositivity
Outcomes of interest for the longitudinal analysis are the
following newly developed metabolic diseases/risk factors: type 2
diabetes, obesity, relative weight change increase, hypertension,
and dyslipidemia. These variables were assessed at F4 and
at FF4 as described subsequently. Prevalent cases at F4 were
excluded from the respective longitudinal association analysis
of H. pylori seropositivity at F4 and incident disease/risk factor
at FF4.
Type 2 diabetes was assessed at F4 and FF4 based
on an oral glucose tolerance (OGT) test and the WHO
definition and classification of diabetes mellitus (16), and/or
diabetes medication reported and further validated by hospital
records or by contacting the participants’ treating physicians.
Therefore, this variable contains known validated diabetic
participants (without further OGT test) as well as newly
diagnosed type 2 diabetic participants identified by the OGT
test. Participants with type 1 diabetes (n = 6 at F4) or
unclear diabetes status (n = 38 at F4) were discarded from
the analysis.
Obese participants were identified at F4 and FF4 by a body
mass index (BMI) ≥30 kg/m². The BMI was derived from body
weight and height and expressed in kg/m2. Additionally, the
relative weight change between F4 and FF4 was calculated as the
difference of both weights divided by the weight at F4. Relative
weight change increase was then defined as a relative weight
change greater than zero (yes/no).
Hypertensive participants were identified at F4 and FF4 by
their “actual hypertensive” status (yes/no). Actual hypertensive
participants were identified according to WHO-ISH guidelines
(17) as either normotensive, aware and treated, or hypertensive
and aware (treated or not) or hypertensive and unaware.
Dyslipidemia at F4 and FF4 was defined by laboratory data as
a ratio of total cholesterol to HDL cholesterol greater or equal
to five.
Definition of Covariates
All analyses were adjusted for age, sex, overweight status based
on BMI (if not used as outcome variable), smoking status,
education level, physical activity and alcohol intake. Age was
included as continuous variable. Smoking was categorized into
current, former and never smokers. The education level was
available as low, medium and high representing “Hauptschule
/ Volksschule,” “Mittlere Reife / Realschule,” and “Abitur /
Fachabitur / Fachhochschulreife,” respectively. Alcohol intake
was coded as none, medium (up to 40 g/day) and high (more
than 40 g/day) based on an already categorized alcohol intake
variable. Participants were classified as physically inactive when
they reported to do sport activities irregularly or <1 h per week
in both seasons and as physical active otherwise.
The following variables were included in the descriptive
analysis and the cross-sectional analysis: continuous BMI,
known gout or increased serum uric acid concentration (the
corresponding question assessed a physician-based diagnosis
during the last 12 months), known gastritis (last 12 months),
known inflammatory bowel disease (last 12 months) gastric or
duodenal ulcer (last 12 months). In addition, information on
the following laboratory data was included: total cholesterol
(mmol/L), fasting plasma glucose (mmol/L), and cytotoxin-
associated gene-A (CagA) positivity (>1,800 MFI).
Statistical Analysis
A descriptive analysis of all participants who had their HP
status available at F4 and FF4 (n = 2,075) was carried out.
We report absolute and relative numbers for all adjustment
variables and clinical characteristics of interest that had been
described above. Further, means and standard deviations (SD)
are given for the laboratory data. To compare the groups defined
by H. pylori seropositivity the Wilcoxon rank sum test for
continuous variables and the chi²-test for categorical variables
were applied.
To describe the prevalence of acute and past H. pylori
infection, age-standardized proportions were calculated for the
KORA F4 population. As a reference group, the age distribution
in Germany in the year 2007 was used, split into 10 year intervals
(18). All participants with availableH. pylori status were included
in the analyses at F4, resulting in n= 3,037.
A cross-sectional approach was applied to identify
associations of H. pylori seropositivity at F4. In the logistic
regression model, all covariates and clinical outcomes described
above were included. The odds ratio (OR) and 95% confidence
interval (CI) are reported.
In a longitudinal design, we aimed to identify associations of
H. pylori seropositivity at the F4 survey and incident metabolic
diseases/risk factors at FF4. As mentioned before, prevalent cases
at F4 were excluded from the respective analysis. For each
outcome we fitted three generalized regression models using
the log-link function to estimate relative risks (RR). Model
1 represents a raw model, adjusting only for age and sex.
Model 2 additionally included obesity, physical activity, smoking
status, education level, and alcohol consumption as covariates.
Model 3 is a fully adjusted model, including also information
on hypertension, dyslipidemia, type 2 diabetes and gout or
increased uric acid. When investigating newly developed obesity,
relative weight change increase, hypertension, dyslipidemia and
type 2 diabetes, the corresponding adjustment variable was
excluded in models 2 and 3. All adjustment information was
taken from the F4 survey. Effect modification by age and sex
was explored.
As a sensitivity analysis for diabetes, not only were
participants suffering from type 2 diabetes at F4 excluded,
but also those who were identified as pre-diabetic
by the OGT test applied at the F4 examination (16).
Generalized regression models 1, 2, and 3 were fitted.
Further, analogous linear models with fasting plasma
glucose levels as continuous outcome variable were fitted
as sensitivity analyses.
All statistical analyses were performed using R3.3.2.
RESULTS
Study Population
The mean age in the full data set used for calculating the
prevalence was 56.2 years (SD 13.3) at F4 (n = 3,037). Mean
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TABLE 1 | Frequency (%) and mean (SD) of characteristic variables by H. pylori











Age (years) 2,075 52.3 (12.0) 58.2 (11.9) <0.0001
Sex 2,075 0.33
Men 710 (0.48) 294 (0.50)
Women 779 (0.52) 292 (0.50)
Education 2,070 <0.0001
Low 661 (0.44) 352 (0.60)
Medium 411 (0.27) 115 (0.20)
High 416 (0.28) 115 (0.20)
BMI (kg/m2) 2,067 27.0 (4.6) 27.9 (4.7) <0.0001
Obesity (BMI≥30 kg/m2 ) 2,067 0.0005
Yes 323 (0.22) 171 (0.29)
No 1,158 (0.78) 415 (0.71)
Smoking 2,075 0.55
Current 245 (0.16) 102 (0.17)
Former 567 (0.38) 233 (0.40)
Never 677 (0.45) 251 (0.43)
Alcohol intake 2,075 <0.0001
No 385 (0.26) 201 (0.34)
Medium (>0–<40 g/day) 931 (0.62) 315 (0.54)
High (40–>80 g/day) 173 (0.11) 70 (0.12)
Physical activity 2,075 0.13
Active 879 (0.59) 324 (0.55)
Inactive 610 (0.41) 262 (0.45)
CLINICAL CHARACTERISTICS
Diabetes 2,075 0.0002a
No diabetes 1,155 (0.78) 410 (0.70)
Prediabetes 196 (0.13) 100 (0.17)
Type 2 Diabetes 104 (0.07) 66 (0.11)
Other diabetes type 6 (0.00) 0 (0.00)
Unknown 28 (0.02) 10 (0.02)
Hypertension 2,073 <0.0001
Yes 435 (0.29) 241 (0.41)
No 1052 (0.71) 345 (0.59)
Dyslipidemia 2,074 0.65
Yes 289 (0.19) 108 (0.18)
No 1199 (0.81) 478 (0.82)
Gout or increased uric acid 1,875 0.02
Yes 61 (0.04) 33 (0.07)
No 1254 (0.90) 419 (0.86)
Unknown 72 (0.05) 36 (0.07)
Gastritis 1,880 0.082
Yes 88 (0.06) 31 (0.06)
No 1248 (0.90) 443 (0.90)
Unknown 54 (0.04) 16 (0.03)
Inflammatory bowel disease 1,879 0.415
Yes 34 (0.02) 15 (0.03)
(Continued)









No 1319 (0.95) 459 (0.93)
Unknown 35 (0.03) 17 (0.03)
Gastric or duodenal ulcer 1,875 0.678
Yes 14 (0.01) 6 (0.01)
No 1341 (0.97) 469 (0.96)
Unknown 31 (0.02) 14 (0.03)
LABORATORY DATA/SEROLOGY
Total cholesterol (mmol/L) 2,075 215.5 (38.9) 214.6 (37.0) 0.552
Fasting plasma glucose
(mmol/L)
2,062 96.4 (16.6) 97.4 (16.0) 0.053
CagA positive (>1800 MFI) 2,075 111 (0.07) 372 (0.63) <0.0001
*p-value calculated with Wilcoxon rank sum test for continuous variables or chi2-test for
categorical variables. p-values < 0.05 are marked bold.
ap-value calculated without subgroups smaller than 10 persons.
age was 56.7 years (SD 13.4) in men and 55.6 years (SD 13.1) in
women (p < 0.05).
Table 1 shows the baseline characteristics of the 2,075
participants of both surveys stratified by H. pylori seropositivity
status at the F4 survey. The 586 (28.2%) persons with
acute or past H. pylori infection were significantly (p <
0.05) older, less educated, had higher BMI, suffered more
often from prediabetes/diabetes type 2, hypertension, gout or
increased uric acid, and showed differences in alcohol intake
compared with their counterparts. Conversely, no differences
were observed in the prevalence of gastritis, inflammatory
bowel disease, gastric or duodenal ulcer and dyslipidemia. In
addition, the groups did not differ by sex, physical activity,
smoking, total cholesterol, and fasting plasma glucose level.




Based on the 3,037 persons aged between 32 and 82 years
who participated at the F4 survey, the age-standardized
H. pylori prevalence for the year 2007 was 30.2% in men
(n = 1,465) and 28.1% in women (n = 1,572). When
examining the 2,075 participants with information on their
H. pylori status available in both surveys, we found 73
participants who were H. pylori seropositive at the F4
survey, but not at the FF4 survey. On the contrary, we
observed 72 incident cases of H. pylori infection at the
FF4 survey.
Variables Associated With a H. pylori
Seropositivity at the F4 Survey
In the multivariable logistic regression analysis including
2,458 persons with complete covariate data available at
F4, the following factors were significantly associated
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TABLE 2 | Variables associated with H. pylori seropositivity at the F4 survey.
Study population (n = 2,458)* OR (95% CI) p-value**
Sex (women vs. men) 0.88 (0.72–1.08) 0.21
Age (years) 1.04 (1.03–1.05) <0.0001
Body mass index (kg/m2) 1.00 (0.98–1.02) 0.84
Physical activity (inactive vs. active) 1.18 (0.97–1.42) 0.09
Smoking (former vs. current) 0.75 (0.58–0.97) 0.025
Smoking (never vs. current) 0.67 (0.52–0.87) 0.002
Education (medium vs. low) 0.75 (0.60–0.95) 0.016
Education (high vs. low) 0.78 (0.61–1.00) 0.051
Alcohol intake (medium vs. no) 0.73 (0.59–0.90) 0.003
Alcohol intake (high vs. no) 0.72 (0.52–0.99) 0.046
Hypertension (no vs. yes) 0.87 (0.70–1.08) 0.20
Dyslipidemia (no vs. yes) 1.04 (0.83–1.32) 0.72
Type 2 diabetes (no vs. yes) 0.93 (0.67–1.28) 0.65
Gout or increased uric acid (no vs. yes) 0.85 (0.58–1.27) 0.43
Gout or increased uric acid (do not know vs. yes) 0.97 (0.58–1.64) 0.92
Gastritis (no vs. yes) 0.92 (0.64–1.35) 0.67
Gastritis (do not know vs. yes) 0.86 (0.46–1.59) 0.63
Gastric or duodenal ulcer (no vs. yes) 1.01 (0.43–2.48) 0.99
Gastric or duodenal ulcer (do not know vs. yes) 0.92 (0.32–2.70) 0.87
Inflammatory bowel disease (no vs. yes) 1.14 (0.65–2.07) 0.66
Inflammatory bowel disease (do not know vs. yes) 1.13 (0.49–2.60) 0.78
** p-values < 0.05 are marked bold. *n = 579 persons deleted due to missing values.
with a seropositive H. pylori status: increasing age, current
smoking, low education level compared to medium education
level and no alcohol intake. In this cross-sectional design
adjusted for co-variables at the time of the F4 survey, no
associations between metabolic diseases/risk factors (BMI,
type 2 diabetes, hypertension and dyslipidemia, gout or
increased uric acid) and gastrointestinal disease (gastritis,
inflammatory bowel disease, gastric, or duodenal ulcer) were
observed (Table 2).
Associations of Incident Metabolic
Diseases and H. pylori Seropositivity
Table 3 provides an overview of the incident metabolic
diseases/risk factors used as outcome variables and their
frequencies in the 2,075 subjects participating in both surveys.
In the generalized regression model analyses, no significant
associations between H. pylori seropositivity at the time of
the F4 survey and incident metabolic diseases/risk factors at
time of the FF4 survey were observed. Sample size, adjusted
relative risks (RR) and 95% CI of every statistical analysis are
presented in Tables 4, 5. Inclusion of CagA seropositivity in
the models did not change the results (data not shown). For
the outcome “incident diabetes,” we ran a sensitivity analysis
by additionally excluding participants with pre-diabetic status at
F4 from the analysis. This revealed a non-significant increased
risk of newly developed diabetes (model 3: OR 1.93, p = 0.056)
in participants with acute or past H. pylori infection (Table 5).
Further sensitivity analysis on fasting plasma glucose levels led
to similar results (data not shown). Adding the interaction
effects with H. pylori seropositivity to regression model 1 in the
longitudinal analyses did not show effect modification by age and
sex (data not shown).
DISCUSSION
Our results from the population-based KORA study
are in line with earlier data on the prevalence of
H. pylori seropositivity in West Germany. Further, we
confirmed age, education level, smoking and alcohol
intake to be associated with H. pylori seropositivity. The
longitudinal analysis showed no significant association
between H. pylori seropositivity and incident metabolic
diseases/risk factors.
Our finding on the age-standardized H. pylori prevalence
of 30% in men and 28% in women for the year 2007 is in
accordance with an earlier study conducted in West Germany
(19) using H. pylori serology. However, using the same assay
in a population-based study conducted in the 80s in Germany,
Michel, Pawlita (2) reported a H. pylori prevalence of 49%
in men and 48% in women. A recent systematic review
and meta-analysis on global H. pylori prevalence reported
a pooled prevalence estimate for Germany of 35.3% (95%
CI 31.2–39.4) based on eight studies which were conducted
between 1987 and 2010 (1). Six out of these eight German
studies used also serology as method to diagnose H. pylori
infection and revealed prevalence estimates from 31.7% (19)
up to 44.4% (20), depending on study period and region.
It is known from previous studies that H. pylori prevalence
depends on the development status of a country, the study
region within one country, and socioeconomic status of the
participants, see e.g. (21). For Germany, it is known that
depending on the selected areas and study period the prevalence
varies accordingly (22). Prevalence was significantly higher
in all age groups of the eastern part of Germany compared
to West Germany (19, 20, 22). In addition, a decrease in
H. pylori prevalence over time in many developed countries was
described (2, 21).
Our results confirmed that age, education level and alcohol
intake are associated with H. pylori seropositivity, but lipid
levels are not (23). In contrast to the findings of Rosenstock
et al. (23), smoking is significantly associated with H.pylori
seropositivity in our analysis whereas BMI is not. In addition,
we observed no association for type 2 diabetes, hypertension
and dyslipidemia, which is in accordance with the results
from earlier cross-sectional studies, see e.g. (23, 24). Age, sex,
BMI, and education level have been reported to be related to
H. pylori infection earlier (25), as well as an inverse association
with alcohol consumption (26) and, among other factors,
socioeconomic status (22). Interestingly we did not find an
association between gastro-intestinal diseases such as gastritis
and gastric or duodenal ulcer and H. pylori seropositivity.
One explanation might be that our population includes a
high number of symptom-free and/or successfully treated
H. pylori infections.
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TABLE 3 | Metabolic diseases/risk factors defined as outcome variables and their frequencies in participants assessed at the FF4 survey.
Outcome variables Assessment at the FF4 survey Sample size for regression analysis*
Yes No Not known
Relative weight change increase 1154 913 8 2,067
Incident type 2 diabetes 1,670 130 99 1,800
Incident hypertension 227 1,168 4 1,395
Incident dyslipidemia 216 1,857 2 2,073
Incident obesity 137 1,436 8 1,571
*Sample size varies by outcome variable due to different number of excluded persons who suffered already from the disease at F4, or reported at F4 and/or at FF4 that they do not
know about the disease.
TABLE 4 | Association of H. pylori seropositivity with incident hypertension, obesity, and relative weight change increase.
Analysis Incident hypertension (yes/no) Incident obesity (yes/no) Relative weight change increase (yes/no)
Sample size* RR (95% CI) p-value Sample size* RR (95% CI) p-value Sample size* RR (95% CI) p-value
Model 1a 1,395 1.15 (0.90;1.47) 0.28 1,572 0.97 (0.66;1.40) 0.89 2,067 1.02 (0.93;1.11) 0.73
Model 2b 1,385 1.02 (0.81;1.28) 0.87 1,569 0.90 (0.61;1.31) 0.60 2,062 1.02 (0.93;1.12) 0.61
Model 3c 1,297 1.10 (0.86;1.42) 0.44 1,405 0.96 (0.63;1.41) 0.84 1,825 1.03 (0.94; 1.13) 0.46
*Sample sizes of the models were based on complete case for outcome variables and respective co-variables.
aAdjusted for age (cont.) and sex.
bAdditional adjustment for physical activity, education, alcohol intake, smoking, and obesity (not for the outcomes “incident obesity” and “relative weight change increase”).
cAdditional adjustment for all other clinical characteristics (diabetes, dyslipidemia, hypertension, and gout or increased uric acid levels) with assessment at F4.
An explanation for the association of alcohol intake and
H. pylori seropositivity might be that besides the bactericidal
effect, alcoholic beverages stimulate gastric acid secretion. This
could result in lowering the pH in the stomach, which could
impact the H. pylori load (27, 28). Regarding the association
of smoking and H. pylori infection, Endoh and Leung (29)
suggested that nicotine reduces gastric mucosal blood flow,
epidermal growth factor secretion, and mucus secretion, thus
facilitating H. pylori colonization (30). Not every H. pylori
infected participant will develop gastric atrophy (11). This
aspect could also have influenced our results in the longitudinal
analysis, where we did not observe a significant association
of H. pylori seropositivity and incident metabolic diseases/risk
factors. H. pylori infections can be seen as the most important
cause of gastritis and the development of gastric and duodenal
ulcer (31). A reason for the non-associations found in our
longitudinal analysis could be the relatively short follow-up-time
of 6–9 years between the two surveys. Therefore, a seropositive
H. pylori status in the participants without significantly higher
frequencies of gastrointestinal risk factors such as gastritis or
peptic ulcer disease at baseline (F4 survey) might need longer
periods and cofactors to evolve non-gastrointestinal diseases
due to inflammatory processes suggested in the pathogenesis
of those diseases (21). Although the frequency of CagA-
positive strains within the H. pylori infected patients in our
study was higher (63%) compared with an earlier study in
Eastern Germany (32), inclusion of this virulence factor did
not change the present results. Earlier prospective cohort
studies regarding the impact of H. pylori infection on the
incidence of diabetes reported contradictory results (10, 11).
In addition, a recent meta-analysis reported increased risks of
type 1 and type 2 diabetes mellitus with H. pylori infection
for the included 17 case-control studies, but no significance
was observed for the 2 included cohort studies (33). As a
longitudinal design is mandatory for investigating incident
cases without the limitation of potential “reverse causality,”
our prospective study adds further non-significant findings
about a potential association between H. pylori seropositivity
and incident diabetes. To answer the conflicting results on
diabetes risk, further prospective studies might be necessary
in participants without prevalent diabetes or prediabetes. The
diagnosis of an H. pylori infection should also be based
on histology obtained by endoscopy to identify all cases.
Furthermore, an association between H. pylori infection and
newly developed obesity, hypertension, dyslipidemia or relative
weight change increase was not observed in our study. As
previous studies investigating cardiovascular diseases (9, 34),
hypertension (35), lipid profile (3, 35–37), obesity (3), and BMI
(35, 36, 38) have been mainly cross-sectional or ecological,
rather than prospective in design, little evidence exists so far for
meaningful causative associations.
Because our results are based on a representative sample of
the German population, plausible estimates of current H. pylori
prevalence could be reported. Age, education level, smoking and
alcohol intake were associated withH. pylori seropositivity. Based
on the findings of missing associations between acute or past
H. pylori infection and incident metabolic diseases/risk factors,
we conclude that further prospective studies covering a sufficient
time span along with histological confirmation of activeH. pylori
infection are required.
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TABLE 5 | Association of H. pylori seropositivity with incident type 2 diabetes and dyslipidemia.
Analysis Incident type 2 diabetes Incident dyslipidemia
In persons without type 2 diabetes at F4 In persons without type 2 diabetes or prediabetes at F4
Sample size* RR (95% CI) p-value Sample size* RR (95% CI) p-value Sample size* RR (95% CI) p-value
Model 1a 1,800 1.07 (0.76;1.50) 0.69 1,513 1.77 (0.92;3.33) 0.08 2,073 0.91 (0.67;1.21) 0.53
Model 2b 1,795 0.93 (0.66;1.30) 0.65 1,508 1.55 (0.81;2.94) 0.18 2,060 0.82 (0.61;1.09) 0.18
Model 3c 1,646 1.08 (0.76;1.52) 0.68 1,411 1.93 (0.98;3.61) 0.06 1,824 0.85 (0.62;1.14) 0.28
aAdjusted for age (cont.) and sex.
bAdditional adjustment for obesity, physical activity, education, alcohol intake, and smoking.
cAdditional adjustment for the baseline variables hypertension, gout, or increased uric acid blood levels, and diabetes or dyslipidemia (depending on outcome parameter).
*Sample sizes of the models were based on complete case for outcome variables and respective co-variables.
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